ID   J-Lat 9.2
AC   CVCL_8285
SY   J-Lat clone 9.2; J-Lat full length clone 9.2
DR   cancercelllines; CVCL_8285
DR   HIVReagentProgram; ARP-9848
DR   Wikidata; Q54898419
RX   PubMed=12682019;
RX   PubMed=18692772;
RX   PubMed=26912621;
RX   PubMed=28086908;
CC   Population: Caucasian.
CC   Virology: Latently infected with HIV-1 strain R7/E-/GFP. The integrated HIV-1 genome is located in PP5 4th intron (PubMed=18692772; PubMed=26912621; PubMed=28086908).
CC   Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Argfs*19 (c.121delG); ClinVar=VCV000009512; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Glyfs*33 (c.121dupG); ClinVar=VCV000009511; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Cys (c.1513C>T); ClinVar=VCV000069961; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; p.Gln345Ter (c.1033C>T); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; c.1097+1065_1097+1112del47; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 7325; MSH2; Simple; p.Arg711Ter (c.2131C>T); ClinVar=VCV000090903; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Serfs*2 (c.3261delC); ClinVar=VCV000089363; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Heterozygous (from parent cell line).
CC   Transfected with: UniProtKB; P42212; GFP.
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
CC   Cell type: T-cell; CL=CL_0000084.
DI   NCIt; C7953; Childhood T acute lymphoblastic leukemia
DI   ORDO; Orphanet_99861; Precursor T-cell acute lymphoblastic leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0065 ! Jurkat
SX   Male
AG   14Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 23
//
RX   PubMed=12682019; DOI=10.1093/emboj/cdg188;
RA   Jordan A., Bisgrove D., Verdin E.;
RT   "HIV reproducibly establishes a latent infection after acute infection
RT   of T cells in vitro.";
RL   EMBO J. 22:1868-1877(2003).
//
RX   PubMed=18692772; DOI=10.1016/j.chom.2008.05.016;
RA   Lenasi T., Contreras X., Peterlin B.M.;
RT   "Transcriptional interference antagonizes proviral gene expression to
RT   promote HIV latency.";
RL   Cell Host Microbe 4:123-133(2008).
//
RX   PubMed=26912621; DOI=10.1128/JVI.01617-15;
RA   Sunshine S., Kirchner R., Amr S.S., Mansur L., Shakhbatyan R., Kim M.,
RA   Bosque A., Siliciano R.F., Planelles V., Hofmann O., Sui S.H.,
RA   Li J.Z.;
RT   "HIV integration site analysis of cellular models of HIV latency with
RT   a probe-enriched next-generation sequencing assay.";
RL   J. Virol. 90:4511-4519(2016).
//
RX   PubMed=28086908; DOI=10.1186/s12977-016-0325-2;
RA   Symons J., Chopra A., Malatinkova E., De Spiegelaere W., Leary S.,
RA   Cooper D., Abana C.O., Rhodes A., Rezaei S.D., Vandekerckhove L.,
RA   Mallal S., Lewin S.R., Cameron P.U.;
RT   "HIV integration sites in latently infected cell lines: evidence of
RT   ongoing replication.";
RL   Retrovirology 14:2.1-2.11(2017).
//